Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.

Hillaireau H, Dereuddre-Bosquet N, Skanji R, Bekkara-Aounallah F, Caron J, Lepêtre S, Argote S, Bauduin L, Yousfi R, Rogez-Kreuz C, Desmaële D, Rousseau B, Gref R, Andrieux K, Clayette P, Couvreur P.

Biomaterials. 2013 Jul;34(20):4831-8. doi: 10.1016/j.biomaterials.2013.03.022. Epub 2013 Apr 2.

PMID:
23562054
[PubMed - indexed for MEDLINE]
2.

Strategies in the design of prodrugs of anti-HIV agents.

Calogeropoulou T, Detsi A, Lekkas E, Koufaki M.

Curr Top Med Chem. 2003;3(13):1467-95. Review.

PMID:
14529522
[PubMed - indexed for MEDLINE]
3.

Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.

Miller V, Larder BA.

Antivir Ther. 2001;6 Suppl 3:25-44. Review.

PMID:
11678471
[PubMed - indexed for MEDLINE]
4.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM.

Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Review.

PMID:
20000887
[PubMed - indexed for MEDLINE]
5.

Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

Sluis-Cremer N, Arion D, Parniak MA.

Cell Mol Life Sci. 2000 Sep;57(10):1408-22. Review.

PMID:
11078020
[PubMed - indexed for MEDLINE]
6.

Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.

Anderson KS.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):296-9. Review.

PMID:
12084471
[PubMed - indexed for MEDLINE]
7.

An introduction to nucleoside and nucleotide analogues.

Squires KE.

Antivir Ther. 2001;6 Suppl 3:1-14. Review.

PMID:
11678469
[PubMed - indexed for MEDLINE]
8.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
9.

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.

Piliero PJ.

J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S2-S12. Review.

PMID:
15319664
[PubMed - indexed for MEDLINE]
10.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
[PubMed - indexed for MEDLINE]
11.

[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].

Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G.

Infez Med. 2006 Jun;14(2):61-70. Review. Italian.

PMID:
16891850
[PubMed - indexed for MEDLINE]
Free Article
12.

Squalenoylation: a generic platform for nanoparticular drug delivery.

Desmaële D, Gref R, Couvreur P.

J Control Release. 2012 Jul 20;161(2):609-18. doi: 10.1016/j.jconrel.2011.07.038. Epub 2011 Aug 4. Review.

PMID:
21840355
[PubMed - indexed for MEDLINE]
13.

New developments in anti-HIV chemotherapy.

De Clercq E.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):258-75. Review.

PMID:
12084468
[PubMed - indexed for MEDLINE]
14.

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N, Caliò R.

J Leukoc Biol. 1997 Jul;62(1):138-43. Review.

PMID:
9226005
[PubMed - indexed for MEDLINE]
Free Article
15.

New nucleoside/nucleotide backbone options: a review of recent studies.

Ruane PJ, DeJesus E.

J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S21-9. Review.

PMID:
15319666
[PubMed - indexed for MEDLINE]
16.

Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.

Smith M, Salomon H, Wainberg MA.

Clin Invest Med. 1994 Jun;17(3):226-43. Review.

PMID:
7523016
[PubMed - indexed for MEDLINE]
17.

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

Cihlar T, Ray AS.

Antiviral Res. 2010 Jan;85(1):39-58. doi: 10.1016/j.antiviral.2009.09.014. Epub 2009 Nov 1. Review.

PMID:
19887088
[PubMed - indexed for MEDLINE]
18.

[Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse transcriptase inhibitor].

Okiyama M, Kawashima H, Fukunishi S.

Nihon Yakurigaku Zasshi. 2002 Aug;120(2):115-22. Review. Japanese.

PMID:
12187624
[PubMed - indexed for MEDLINE]
19.

Novel approaches for designing 5'-O-ester prodrugs of 3'-azido-2', 3'-dideoxythymidine (AZT).

Parang K, Wiebe LI, Knaus EE.

Curr Med Chem. 2000 Oct;7(10):995-1039. Review.

PMID:
10911016
[PubMed - indexed for MEDLINE]
20.

Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

Bongiovanni M, Tordato F.

Curr Med Chem. 2006;13(23):2789-93. Review.

PMID:
17073629
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk